CYP19A1 and breast carcinoma: Generally, following local therapy for pure DCIS, 5 years of endocrine therapy with either tamoxifen or an aromatase inhibitor is recommended for ER- and/or PR-positive patients to reduce the risk of ipsilateral breast events and contralateral breast cancer.